AsymBio Establishes Integrated Technology Platforms Spanning the Full Biopharmaceutical Development Lifecycle
Il sito "il Centro Tirreno.it" utilizza cookie tecnici o assimiliati e cookie di profilazione di terze parti in forma aggregata a scopi pubblicitari e per rendere più agevole la navigazione, garantire la fruizione dei servizi, se vuoi saperne di più leggi l'informativa estesa, se decidi di continuare la navigazione consideriamo che accetti il loro uso.
Informativa estesa
20
Gio, Ago

Abbiamo 5188 visitatori e nessun utente online

AsymBio Establishes Integrated Technology Platforms Spanning the Full Biopharmaceutical Development Lifecycle

Immediapress
Typography
  • Smaller Small Medium Big Bigger
  • Default Helvetica Segoe Georgia Times

COMUNICATO STAMPA - CONTENUTO PROMOZIONALE

SHANGHAI, Feb. 10, 2026 /PRNewswire/ -- AsymBio, a subsidiary of Asymchem Group (stock code: 002821.SZ / 6821.HK), announced that it has established integrated technology platforms spanning the full biopharmaceutical development lifecycle. Through its end-to-end service capabilities, the company

provides streamlined, integrated workflows from early development to commercial manufacturing. 

AsymBio is a technology-driven biopharmaceutical CDMO focused on accelerating innovation through integrated development and manufacturing services for clients. Key platforms include: 

AsymBio will continue to invest in R&D and technology development through advanced technology platforms and data-enabled manufacturing processes. By integrating advanced scientific approaches with large-scale manufacturing experience, AsymBio works to help global clients address complex development challenges, improve manufacturing efficiency and product quality, and support reliable commercialization of innovative therapies. 

About AsymBio 

AsymBio focuses exclusively on biopharmaceutical CDMO services. The company delivers one-stop CDMO services from early-stage development to clinical, toxicology, and commercial-scale manufacturing. AsymBio is also expanding beyond ADCs into NDCs while maintaining comprehensive capabilities for antibody therapeutics and recombinant proteins. 

For more information, visit www.asymbio.com or follow us on LinkedIn.Business inquiries: Questo indirizzo email è protetto dagli spambots. È necessario abilitare JavaScript per vederlo.  

Logo - https://mma.prnewswire.com/media/2888481/5775993/AsymBio_Logo.jpg  

View original content:https://www.prnewswire.co.uk/news-releases/asymbio-establishes-integrated-technology-platforms-spanning-the-full-biopharmaceutical-development-lifecycle-302682462.html  

Copyright 2026 PR Newswire. All Rights Reserved. 

COMUNICATO STAMPA - CONTENUTO PROMOZIONALE: Immediapress è un servizio di diffusione di comunicati stampa in testo originale redatto direttamente dall'ente che lo emette. L'Adnkronos e Immediapress non sono responsabili per i contenuti dei comunicati trasmessi

Author: RedWebsite: http://ilcentrotirreno.it/Email: Questo indirizzo email è protetto dagli spambots. È necessario abilitare JavaScript per vederlo.